William Blair analyst Matt Phipps has reiterated their bullish stance on GMAB stock, giving a Buy rating on October 27.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Matt Phipps has given his Buy rating due to a combination of factors including Genmab’s strong financial performance and promising pipeline developments. The company reported third-quarter revenues that exceeded expectations, driven by higher royalties and product sales, which indicates robust financial health and steady revenue growth.
Furthermore, despite a slight miss in Epkinly sales, the overall guidance remains intact, and the company is on track with its late-stage pipeline developments. With several significant catalysts anticipated towards the end of 2025 and into 2026, including potential FDA approvals and pivotal trial readouts, Genmab’s pipeline holds the potential for long-term revenue growth, reinforcing the Buy rating.
Phipps covers the Healthcare sector, focusing on stocks such as Merus, Upstream Bio, Inc., and Bristol-Myers Squibb. According to TipRanks, Phipps has an average return of 2.0% and a 44.98% success rate on recommended stocks.